Innovative Eyewear Inc LUCYW

Healthcare SIC 3851 - Ophthalmic Goods Nasdaq

We develop and sell cutting-edge smart eyewear – including prescription eyeglasses, ready-to-wear sunglasses, safety glasses, and sport glasses – that is designed to allow our customers to remain connected to their digital lives.

Founded and headquartered in Miami, Florida, we were initially organized as a Florida limited liability company effective August 15, 2019. On March 26, 2020, we converted from a Florida limited liability company into a Florida corporation.

We were founded by Lucyd Ltd., the inventor of the technology that our products are based upon, which is a portfolio company of Tekcapital Europe Ltd. ("Tekcapital"). Tekcapital is a U.K. based university intellectual property accelerator which builds portfolio companies around new technologies.

Last close 0.03 2026-09-04
Market cap $275.5K 2026-06-30 share count
52-week range 0.03 - 0.18

Valuation FY2025 figures against the last close

P/S0.1x
P/E
P/FCF
EV/EBITDA
Dividend yield
Diluted EPS-1.90

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Revenue $2.7M$1.6M$1.2M$659.8K$690.7K
Cost of revenue $2.1M$1.4M$1.3M$716.1K$542.4K
Gross profit $567.5K$215.2K-$119.3K-$56.3K$148.3K
R&D $725.4K$819.4K$662.2K$524.7K$86.3K
SG&A $5.2M$4.5M$3.9M$2.8M$1.4M
Total operating expenses $9.1M$8.1M$6.7M$5.5M$3.4M
Interest expense $3.0K$105.2K$39.4K
Net income -$7.6M-$7.8M-$6.7M-$5.7M-$3.2M
EPS, basic -1.90-5.19-10.87-0.87
EPS, diluted -1.90-5.19-10.87-0.87
Shares, diluted (wtd. avg.) $4.0M$1.5M$613.0K$6.5M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents $6.5M$2.6M$4.3M$3.6M$79.7K$27.0K
Receivables $142.2K$107.9K$93.2K$110.3K$43.4K
Inventory $1.7M$831.8K$533.2K$94.7K$275.5K
Total current assets $9.4M$9.2M$5.6M$4.2M$644.3K
Property, plant and equipment $61.8K$107.6K$154.8K$119.7K$20.3K
Other intangibles $560.0K$451.3K$286.4K$137.6K$87.3K
Total assets $10.1M$9.8M$6.2M$4.7M$824.3K
Accounts payable $985.4K$692.8K$582.0K$275.7K$167.1K
Total current liabilities $1.0M$737.7K$624.5K$600.0K$616.8K
Total liabilities $1.1M$743.2K$659.9K$665.5K$616.8K
Retained earnings -$32.3M-$24.7M-$17.0M-$10.3M-$4.6M
Total equity $9.1M$9.1M$5.6M$4.0M$207.5K-$554.8K

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Operating cash flow -$7.3M-$6.7M-$5.8M-$3.2M-$1.2M
Depreciation and amortisation $66.8K$109.5K$61.1K$22.1K$498
Stock-based compensation $738.2K$774.8K$936.8K$1.5M$1.3M
Capital expenditure $72.5K$62.2K$78.5K$121.6K$20.8K
Investing cash flow $4.5M-$5.2M-$198.8K-$220.0K-$118.5K
Financing cash flow $6.7M$10.2M$6.7M$7.0M$1.4M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001829126-26-002695.

Others in SIC 3851

TickerCompanyMarket capP/ERevenue growth
COO COOPER COMPANIES, INC. $13.57B 37.2x 5.1%
BLCO Bausch & Lomb Corp $6.44B 6.5%
WRBY Warby Parker Inc. $3.02B 2,435.0x 13.0%
EYE National Vision Holdings, Inc. $1.32B 45.2x 9.0%
STAA STAAR SURGICAL CO $1.18B -23.7%
RXST RxSight, Inc. $265.2M -3.9%
ALC ALCON INC 4.9%